We enable longer and healthier living through detection and monitoring of serious disease

At Chembio, our mission is to be a leader in the development, manufacture and commercialization of diagnostic solutions. We are dedicated to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). As a global company, we are committed to innovation and the highest quality standards.

At the core of our commitment is our patented Next Generation DPP® (Dual Path Platform) technology. Our DPP® technology is a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including:

Significantly improved sensitivity

Multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay)

Application in a number of indications

Today our DPP® technology is the basis of multiple collaborations with healthcare innovators and leaders worldwide spanning infectious diseases such as HIV, Zika, Ebola, syphilis, malaria and febrile illness, as well as potential new uses in the diagnosis of a specific form of cancer and brain injury (concussion).

Medford, US
Size (employees)
131 (est)-15%
Chembio was founded in 1986 and is headquartered in Medford, US

Chembio Office Locations

Chembio has an office in Medford
Medford, US (HQ)
3661 Horseblock Road

Chembio Data and Metrics

Chembio Financial Metrics

Chembio's revenue was reported to be $17.9 m in FY, 2016 which is a 26% decrease from the previous period.
$, USD

Revenue (FY, 2016)

17.9 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

8.5 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(13.3 m)

EBIT (FY, 2016)

(7.6 m)

Market capitalization (23-Jun-2017)

77.5 m

Closing share price (23-Jun-2017)


Cash (31-Dec-2016)

10.6 m
Chembio's current market capitalization is $77.5 m.
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


29.5 m27.6 m24.3 m17.9 m

Revenue growth, %


Cost of goods sold

17.2 m16.8 m13.8 m9.4 m

Gross profit

12.3 m10.8 m10.5 m8.5 m

Gross profit Margin, %


Operating expense total

11.3 m12.4 m14 m16 m


1 m(1.6 m)(3.6 m)(7.6 m)

EBIT margin, %


Interest expense


Interest income

5.8 k5.8 k2.4 k25.5 k

Pre tax profit

1 m(1.6 m)(3.6 m)(7.5 m)

Income tax expense

487 k(412.9 k)(1.2 m)5.8 m

Net Income

530.8 k(1.1 m)(2.4 m)(13.3 m)
$, USDFY, 2013FY, 2014FY, 2015FY, 2016


9.7 m4.6 m5.4 m10.6 m


3.2 m3.6 m3.6 m3.3 m

Current Assets

18.5 m17.7 m12.6 m18.1 m


2 m2.8 m2.4 m1.7 m

Total Assets

24.5 m25 m20.8 m20.6 m

Current Liabilities

4.3 m5.3 m3.2 m3.4 m

Additional Paid-in Capital

46.9 m47.6 m47.9 m60.7 m

Retained Earnings

(26.8 m)(27.9 m)(30.3 m)(43.7 m)

Total Equity

20.2 m19.7 m17.7 m17.2 m

Financial Leverage

1.2 x1.3 x1.2 x1.2 x
$, USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

530.8 k(1.1 m)(2.4 m)(13.3 m)

Depreciation and Amortization

607.8 k739.3 k1.4 m1.1 m

Accounts Receivable

263.2 k(3.8 m)5.9 m(960.8 k)


(700.7 k)(449.6 k)60.3 k242.8 k

Cash From Operating Activities

2.3 m(3.8 m)1.8 m(6.7 m)

Cash From Investing Activities

(885.6 k)(1.5 m)(1 m)(668.7 k)

Cash From Financing Activities

5.3 m237.2 k12.6 m
$, USDY, 2016


115.3 k

Financial Leverage

1.2 x

Chembio Operating Metrics

FY, 2016

Patents (US)




Chembio Market Value History

Chembio Revenue Breakdown

Chembio Online and Social Media Presence

Chembio Company Life and Culture

You may also be interested in